Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Hana Micron (067310) – Change in Revenue or Income Structure Exceeding 30% (15% for Large Corporations) / 2024-03-13

Posted on March 13, 2024August 2, 2026 By K-STOCK Editor No Comments on [Disclosure] Hana Micron (067310) – Change in Revenue or Income Structure Exceeding 30% (15% for Large Corporations) / 2024-03-13

Fact Source: Financial Supervisory Service DART

💡 Executive Summary

Hana Micron reported FY2023 consolidated revenue of KRW 967.97 billion (up 8.2% YoY), but experienced a sharp drop in profitability with operating profit falling 44.1% to KRW 57.90 billion and net profit dropping 97.8% to KRW 1.28 billion due to the semiconductor industry slowdown.

📊 Key Disclosure Content & Financial Figures Summary

  1. Company Name: Hana Micron Inc.
  2. Financial Statement Type: Consolidated Financial Statements
  3. Details of Changes in Income Structure (Unit: KRW):
    • Revenue: 967,971,484,717 (YoY +8.2%)
    • Operating Profit: 57,904,676,214 (YoY -44.1%)
    • Income Before Income Taxes: 14,234,230,932 (YoY -84.3%)
    • Net Profit: 1,276,797,848 (YoY -97.8%)
  4. Key Financial Position (Unit: KRW):
    • Total Assets: 1,723,699,033,076
    • Total Liabilities: 1,181,829,207,193
    • Total Equity: 541,869,825,883 (Capital Stock: 23,989,927,000)
  5. Primary Cause of Changes: Decrease in profitability due to sluggish conditions in the downstream semiconductor industry
  6. Board Resolution Date: March 13, 2024 (1 Outside Director attended, Auditor attended)

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Profitability Changes and Upcoming Final Audit Report

This filing discloses a significant change (exceeding 30%) in earnings structure for FY2023. Reviewing the impact of the semiconductor industry slowdown on profitability and tracking potential post-audit adjustments in the upcoming final audit report is necessary. Further details can be verified through this disclosure and the Korea Exchange KIND system.

📢 Disclaimer & Source Information

Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Disclaimer: This content is provided solely for information purposes and linguistic reference. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific securities. All investment decisions and financial risks rest solely with the investor.

Contact: For compliance inquiries or copyright-related issues, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] Hana Micron (067310) – Resolution on Convocation of General Shareholders’ Meeting / 2024-03-13
Next Post: [Disclosure] Hana Micron (067310) – Decision on Cash/In-Kind Dividend / 2024-03-13

Related Posts

[Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for ALT-B4 / 2026-01-20 Disclosures
[Disclosure] Samsung Biologics (207940) – Change of 15% or More in Revenue or Profit/Loss Structure (Large-Scale Company) / 2025-01-22 Disclosures
[Disclosure] Celltrion (068270) – Application for Amendment of Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in Korea / 2026-03-30 Disclosures
[Disclosure] Hanwha Aerospace (012450) Signs Supply Contract Worth Approx. KRW 388.2B with LIG Nex1 for IM3 Project Launcher Mass Production Disclosures
[Disclosure] SK hynix (000660) – Decision on Business Transfer / 2026-01-28 Semiconductors
[Disclosure] Hanwha Aerospace (012450) to Sign KRW 2.22T Follow-up Contracts with Subsidiary to Execute Poland Chunmoo Project Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme